Research Breakdown on Benfotiamine
Benfotiamine is a molecule with the proper name of S-benzoylthiamine O-monophosphate and is a derivative of Vitamin B1, Thiamine. After oral ingestion, it can be converted to Thiamin and is thus considered a prodrug for Thiamin. with another suggesting that to reach the same circulating levels of Thiamin only 40% an oral dose of Benfotiamine is needed. This enhanced bioavailability is thought to be related to the structure, where the novel open thiazole-ring enables passive membrane transport secondary to being phosphorylated (in the brush border of the intestines) to S-benzoylthiamine by ecto-alkaline phosphatase.
Benfotiamine appears to have better absorption than other Thiamin-related structures that get metabolized into free Thiamin
Relatively quick serum spikes in Thiamin resulting from Benfotiamine ingestion These metabolites can also be detected in dorsal root ganglia and the dorsal spinal cord of rats, but to a much lesser degree in neural tissue (2.3-fold increase at 300mg/kg); this has been noted elsewhere.
Benfotiamine can increase tissue concentrations of Thiamin and Thiamin-related compounds after oral administration to rats this then passively degrades into O-benzoylthiamine and is converted into active Thiamin via a thioesterase-dependent mechanism; some passive degradation may occur to Thiamin under alkaline conditions in vitro. Metabolism in the liver to Thiamin by thoiesterase enzymes also yields free benzoic acid. In mice (either diabetic by streptozotocin or normal mice) given Benfotiamine at 100mg/kg for 14 days was able to normalize the glutathione:glutathione disulfide (GSSG) ratio in the cerebral cortex (by decreasing GSSG to control levels), although it did not affect normal mice. These benefits occurred prior to any changes in AGEs or TNF-α (and thus were independent). and against capsaicin-induced (injections) writhing, the ED50 dose of Benfotiamine injections appears to be 529.4+/-85.2mg/kg; this was lower than resveratrol (ED50 104+/-8.2mg/kg) but the two appears to be synergistic. Pain reduction has also been noted in chronic models of pain such as CFA injection (a chemical mimetic of Rheumatoid Arthritis) with near complete normalization at 300mg/kg oral ingestion. Other rat studies conducted on pain note that both diabetic and non-diabetic rats experience reduction in pain at 75-300mg/kg Benfotiamine (10mg/kg not being statistically significant). One study in Diabetic Polyneuropathy has noted that while the Global rating scores slightly failed to reach statistical significance, 300-600mg of Benfotiamine daily was associated with significant reductions on the pain subset of the Diabetic Polyneuropathy rating scale in particular.
Able to reduce pain perception following intravenous and oral dosing, with varying potency depending on the manner of stressor (chemical or environmental)The enzyme Prostatic Acid phosphatase is required for pain relief from Benfotiamine, although it appears to be required for Thiamin-induced pain relief and may be indepedent of metabolism from Benfotiamine into Thiamin. Metabolism of Benfotiamine to Thiamin was not actually attenuated in this study, suggesting that PAP is not mandatory for conversion yet has novel pain interactions. High dose intravenous Benfotiamine therapy (100mg/kg) for 14 days appears to benefit cardiac function in streptozotocin-induced diabetic mice independent of AGE formation. Benfotiamine (70mg/kg oral ingestion for four weeks) was later shown to preserve signalling via an Akt/Pim-1 pathway (PI3K dependent) secondary to its transketolase inducing ability. This pathway is protective of cardiomyocyte cells, but is hindered during periods of high blood glucose since STAT3 is downregulation (normally preserves Pim-1) and then PP2A is induced (suppresses Pim-1); Benfotiamine prevented STAT3 downregulation (without affecting PP2A) and preserved Pim-1, which then preserved the cardioprotective signalling via Akt/Pim-1.
Appears to protect cardiomyocytes (cardiac muscle cells) in response to stressors, either prolonged during reducing AGE formation (which ties into diabetic cardiomyopathy) or acutely via anti-oxidative effects. Has not yet been demonstrated to benefit cardiac tissue when a stressor is not otherwise incubated, suggesting preventative but not enhancing properties A small study (n=13 Type II Diabetics) involving a high heat processed meal (to concentrate AGE content, also had a high carbohydrate content) before and after a 3 day period where they were given 1050mg Benfotiamine noted that supplementation was able to preserve flow-mediated vasodilation (which was reduced following the meal prior to Benfotiamine) and Benfotiamine abolished the reactive hyperemia without influencing blood pressure or endothelium-dependent vasorelaxation at either time point. This study also noted that postprandial glucose concentrations were reduced at 2 hours (10%), 4 hours (40%), and 6 hours (22%) relative to the control meal. A similar study design also noted that the postprandial reduction in adiponectin is prevented with supplementation of Benfotiamine. Partial inhibition of GAPDH causes a relative accumulation of the metabolites prior to that enzyme in the glycolytic chain, which include fructose-6-phosphate (F6P) and glyceraldehyde-3-phosphate (G3P); accumulation of these contribute to increased Advanced Glycemic End product (AGE) and Diacylglycerol (DAG) production, and increased metabolic activity of the Hexosamine pathways all of which contribute to microvascular damage and complications associated with Diabetes. Another contributing factor to complications of Microvascularity, increased Polyol synthesis, is independent of F6P and G3P and more related to the Aldose Reductase enzyme. Benfotiamine is seen as helpful in this scenario due to being a transketolase enzyme inducer at concentrations exceeding 50uM, where activity of the enzyme can increase fourfold. Transketolase is a thiamine diphosphate dependent enzyme with a normally low activity in glycolysis, and its activity is further reduced in diabetic patients (as measured in the erythrocytes). Transketolase can reversibly interchange the two products seen as problematic in states of hyperglycemia (F6P and G3P) to D-xylulose-5-phosphate and Erythrose-4-phosphate, and secondary to that reduce the complications that occur with excess cellular accumulation of F6P and G3P. This is sometimes referred to as redirecting glucose substrates towards the pentose phosphate shunt.
Benfotiamine can increase activity of a normally low-active enzyme (transketolase), and in the state of hyperglycemia reduce the buildup of two metabolites which (when in excessive concentrations) contribute to the pathology of diabetic microvasculature damage (damage to small arteries; which is tied to retinopathy, nephropathy, and neuropathy)Additionally, Benfotiamine appears to have direct anti-oxidant properties, which attenuates hyperglycemia induced oxidative damage to the endothelium. Redirection of G3P and F6P via the pentose phosphate shunt and activation of transketolase appears to prevent the decrease in cardiac progenitor cells and may be cardioprotective in states of diabetes.
Various benefits to rats at the above dosesA small study (n=9) in Type 1 Diabetics given 300mg Benfotiamine (twice a day to total 600mg) with Alpha Lipoic Acid (600mg twice a day to total 1200mg) over 28 days was able to enhance transketolase activity (measured in monocytes) 2-3 fold and by 15 days completely normalized serum angiopoietin-2 (a biomarker of methylgloxal adducts in endothelial cells), and effectively normalized (as such that it was not statistically different than non-diabetic control) N-acetylglucosamine modified proteins (indicative of AGE status) and 6-keto-PGF. In diabetics with high-normal proteinuria (protein losses in the urine, in the range of 15–300 mg/24h urinary albumin excretion) taking 300mg thrice a day (totalling 900mg) for a period of 12 weeks failed to provide a significant reduction in serum or urinary Advanced Glycation End products (AGEs); this study also failed to find significant differences in biomarkers of endothelial stress and adhesion factors yet confirmed an increase in thiamine status and transketolase activity. A two year long trial in type I diabetics (over 15 years of diabetes, thought to have reduced nerve conductance velocity) given 300mg Benfotiamine daily failed to note changes in albumin excretion (urinary), HbA1c, nerve conductance measures, or various inflammatory measures. This study has been commented upon and subsequently responded to, but was mostly a defense of methodology.  This former study noted that around 100 and 200 genes were upregulated or downregulated (respectively) after 200uM Benfotiamine, with notable downregulations being NOX4 (2.5-3.1fold), Thymidine phosphorylase (2.2-2.8fold), and MDK (3.3-fold) and notable upregulations of SERPINB7 (2.3-3.4fold increase; more efficacy in normoglycemia) and Carboxypeptidase A4 (1.57-3.16fold; also more efficacy in normoglycemia). Differentiation factors MyoD and Myogenin were not significantly affected.
Possible increase in glucose utilization in skeletal muscle, which may not be related to the two most common pathways (insulin receptor signalling and AMPK activation) and is potentially novelType 1 diabetes was associated with an increase in adipocyte content, Reactive Oxygen Species (ROS), and microangiopathy in bone marrow with reduced density and volume; these effects are prevented in vitro with antioxidants such as N-AcetylCysteine, and oral administration of 70mg/kg Benfotiamine for 24 weeks lessens the degree of oxidative damage in diabetic rats as well as these adverse pathological changes, with the degrees of improvement either trending towards normalization (Bone marrow blood flow), were normalized (LSK cells and density) were were more beneficial than non-diabetic control (TK, Mitochondrial ROS, and G6PDH activity in BMMNCs,). AGE-Albumin is known to interefere with the cholesterol efflux transporters ABCG1 and ABCA1 which appears to be mediated via oxidation. Anti-oxidants in general may reduce these effects (as was established with aminoguanidine), with Benfotiamine confering weak protective effects. Benfotiamine incubation in macrophages has been noted to attenuate LPS induced mitochondrial membrane potential loss in the macrophages, which was thought to be downstream of preventing NF-kB translocation secondary to anti-oxidant effects.
Appears to be an anti-oxidant in immune cells, but is fairly weak at this roleBenfotiamine has been demonstrated to inhibit arachidonic acid (AA) release form RAW264.7 cells, with 100uM Benfotiamine inhibiting approximately 90% of AA release, a similar magnitude of cPLA2 suppression (medites AA release) which was thought to be through a reduction in oxidative stress causing less activation of the pro-inflammatory signalling proteins NF-kB and Er-1; similar mechanisms have been noted elsewhere. Significant improvements were noted in Rheumatoid arthritis disease state as assessed by DAS28 ratings, which was correlated with improvements in inflammatory biomarkers. It was thought that the observed effects were due to direct anti-oxidant properties, as antioxidants in general reduce genomic damage in lymphocytes and Benfotiamine has shown direct anti-oxidant properties that protect the genome in vitro. A significant correlation was noted between transketolase activity and micronucleus frequency though.
Direct anti-oxidant properties that protect DNA have once been shown to be relevant after oral ingestion of Benfotiamine (600mg) by persons at higher risk of genomic damage An approximate halving of albuminuria was noted (in mg/24h) and showed benefit on histological analysis and fibrosis ratings, although not to a remarkable degree. Usage of 70mg/kg Benfotiamine for 24 weeks has been noted to prevent a diabetes-induced increase in AGE adduct formation of renal glomeruli, which is equally potent as a same dose of Thiamin. One human trial has been conducted measuring the degree of urinary albumin excretion (UAE) and and serum levels of KIM-1 (biomarker of kidney damage) in Type II diabetic patients (10-12 disease years) who did not respond to Angiotensin Receptor Blockers (ARBs) or ACE inhibitors who were then given 900mg of Benfotiamine (3x300mg) for 12 weeks, but although there was a trend to reduce UAE rates there was no significant effect on any measured parameter including HbA1c, KIM-1, blood pressure, or cholesterol. was increased to 50-100umol for the Thiamin condition) or Benfotiamine (50-100umol). High glucose conditions (to mimick diabetes) did not alter cell adhesion or proliferation, and the increase in apoptosis from ECM was abolished with all tested doses. This study built off previous studies in bovine pericytes where thiamin acted in a similar manner to aminoguanidine, but was replicated in human pericytes due to species differences. Preventing apoptosis of pericytes is though to be preventative in the early stages of diabetic retinopathy. 7-70mg/kg Benfotiamine in diabetic rats for 24 weeks is also associated with less Advanced Glycemic End product (AGE) adduct formation in the retina, although an equal dose of Thiamin appeared to be more effective; this may be related to transketolase activation.
- Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis.
- Loew D. Pharmacokinetics of thiamine derivatives especially of benfotiamine. Int J Clin Pharmacol Ther. (1996)
- WADA T, et al. A new thiamine derivative, S-benzoylthiamine O-monophosphate. Science. (1961)
- Patel SM, Patel RP, Prajapati BG. Solubility enhancement of benfotiamine, a lipid derivative of thiamine by solid dispersion technique. J Pharm Bioallied Sci. (2012)
- Volvert ML, et al. Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives. BMC Pharmacol. (2008)
- Hurt JK, et al. Prostatic Acid phosphatase is required for the antinociceptive effects of thiamine and benfotiamine. PLoS One. (2012)
- Bitsch R, et al. Bioavailability assessment of the lipophilic benfotiamine as compared to a water-soluble thiamin derivative. Ann Nutr Metab. (1991)
- Balakumar P, et al. The multifaceted therapeutic potential of benfotiamine. Pharmacol Res. (2010)
- Pan X, et al. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Brain. (2010)
- Sun XJ, et al. Benfotiamine prevents increased β-amyloid production in HEK cells induced by high glucose. Neurosci Bull. (2012)
- Wu S, Ren J. Benfotiamine alleviates diabetes-induced cerebral oxidative damage independent of advanced glycation end-product, tissue factor and TNF-alpha. Neurosci Lett. (2006)
- Montiel-Ruiz RM, et al. Antinociceptive interaction between benfotiamine and resveratrol in capsaicin-induced licking. Proc West Pharmacol Soc. (2009)
- Sánchez-Ramírez GM, et al. Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol. (2006)
- Stracke H, et al. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. (2008)
- Ma H, et al. Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy. J Cell Mol Med. (2009)
- Ceylan-Isik AF, et al. High-dose benfotiamine rescues cardiomyocyte contractile dysfunction in streptozotocin-induced diabetes mellitus. J Appl Physiol. (2006)
- Katare RG, et al. Vitamin B1 analog benfotiamine prevents diabetes-induced diastolic dysfunction and heart failure through Akt/Pim-1-mediated survival pathway. Circ Heart Fail. (2010)
- Du Y, Kowluru A, Kern TS. PP2A contributes to endothelial death in high glucose: inhibition by benfotiamine. Am J Physiol Regul Integr Comp Physiol. (2010)
- Stirban A, et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care. (2006)
- Stirban A, et al. Adiponectin decreases postprandially following a heat-processed meal in individuals with type 2 diabetes: an effect prevented by benfotiamine and cooking method. Diabetes Care. (2007)
- Nishikawa T, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. (2000)
- Hammes HP, et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. (2003)
- Tang WH, Martin KA, Hwa J. Aldose reductase, oxidative stress, and diabetic mellitus. Front Pharmacol. (2012)
- Schenk G, Duggleby RG, Nixon PF. Properties and functions of the thiamin diphosphate dependent enzyme transketolase. Int J Biochem Cell Biol. (1998)
- Saito N, et al. Blood thiamine levels in outpatients with diabetes mellitus. J Nutr Sci Vitaminol (Tokyo). (1987)
- Thornalley PJ. The potential role of thiamine (vitamin B1) in diabetic complications. Curr Diabetes Rev. (2005)
- Schmid U, et al. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev. (2008)
- Marchetti V, et al. Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling. Diabetes. (2006)
- Katare R, et al. Boosting the pentose phosphate pathway restores cardiac progenitor cell availability in diabetes. Cardiovasc Res. (2012)
- Du X, Edelstein D, Brownlee M. Oral benfotiamine plus alpha-lipoic acid normalises complication-causing pathways in type 1 diabetes. Diabetologia. (2008)
- Alkhalaf A, et al. Effect of benfotiamine on advanced glycation endproducts and markers of endothelial dysfunction and inflammation in diabetic nephropathy. PLoS One. (2012)
- Fraser DA, et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care. (2012)
- Ziegler D, Tesfaye S, Kempler P. Comment on: Fraser et al. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebo-controlled trial. Diabetes Care 2012;35:1095-1097. Diabetes Care. (2012)
- Fraser DA, et al. Benfotiamine increases glucose oxidation and downregulates NADPH oxidase 4 expression in cultured human myotubes exposed to both normal and high glucose concentrations. Genes Nutr. (2012)
- Oikawa A, et al. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol. (2010)
- de Souza Pinto R, et al. Inhibition of macrophage oxidative stress prevents the reduction of ABCA-1 transporter induced by advanced glycated albumin. Lipids. (2012)
- Passarelli M, et al. Advanced glycation end product precursors impair ABCA1-dependent cholesterol removal from cells. Diabetes. (2005)
- Isoda K, et al. AGE-BSA decreases ABCG1 expression and reduces macrophage cholesterol efflux to HDL. Atherosclerosis. (2007)
- Yadav UC, et al. Protective role of benfotiamine, a fat-soluble vitamin B1 analogue, in lipopolysaccharide-induced cytotoxic signals in murine macrophages. Free Radic Biol Med. (2010)
- Shoeb M, Ramana KV. Anti-inflammatory effects of benfotiamine are mediated through the regulation of the arachidonic acid pathway in macrophages. Free Radic Biol Med. (2012)
- Schupp N, et al. Benfotiamine reduces genomic damage in peripheral lymphocytes of hemodialysis patients. Naunyn Schmiedebergs Arch Pharmacol. (2008)
- Volkovová K, et al. Antioxidant supplementation reduces inter-individual variation in markers of oxidative damage. Free Radic Res. (2005)
- Stirban A, et al. Benfotiamine counteracts smoking-induced vascular dysfunction in healthy smokers. Int J Vasc Med. (2012)
- Kihm LP, et al. Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol. (2011)
- Karachalias N, et al. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia. (2010)
- Alkhalaf A, et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care. (2010)
- High prevalence of low plasma thiamine concentration in diabetes linked to a marker of vascular disease.
- Beltramo E, et al. Thiamine and benfotiamine prevent apoptosis induced by high glucose-conditioned extracellular matrix in human retinal pericytes. Diabetes Metab Res Rev. (2009)
- Beltramo E, et al. A study of capillary pericyte viability on extracellular matrix produced by endothelial cells in high glucose. Diabetologia. (2003)
- Beltramo E, et al. Pericyte adhesion is impaired on extracellular matrix produced by endothelial cells in high hexose concentrations. Diabetologia. (2002)
- Beltramo E, et al. Different apoptotic responses of human and bovine pericytes to fluctuating glucose levels and protective role of thiamine. Diabetes Metab Res Rev. (2009)
- Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res. (1996)
- Beltramo E, et al. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. Acta Diabetol. (2008)